Drug General Information (ID: DDIX4WZ62K)
Drug Name			Palifermin		Drug Info		Trastuzumab		Drug Info
Drug Type		Protein/peptide				Monoclonal antibody
Therapeutic Class		Antimucositis Agents				Antineoplastics

Mechanism of Palifermin-Trastuzumab Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Palifermin				Trastuzumab
Mechanism		Immunomodulatory effects (fibroblast growth factor)				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Palifermin and Trastuzumab

Recommended Action
Management		Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.

References
1	Product Information. Kepivance (palifermin). Shire US Inc, Florence, KY.